October 29, 2015 — Mirada Medical Ltd, a medical imaging software company, and BTG plc, a global specialist healthcare company, announced a collaboration to develop dosimetry software solutions to optimize radioembolization therapy with TheraSphere.
Both companies are working together to provide a more personalized approach to radioembolization for liver cancer patients through easy-to-use and bespoke software that helps physicians plan the delivery of a specific radiation dose based on an individual patient’s need.
Matthieu Leclerc-Chalvet, Mirada Medical managing director commented “Our goal is to provide intuitive software that facilitates the clinician’s use of multimodal images to plan radioembolization therapy with the ultimate aim of leading to better patient outcomes. The collaboration with BTG leverages our image processing expertise and highlights the importance of imaging for planning treatments.”
The companies plan to make the software available in 2016.
For more information: www.mirada-medical.com
March 28, 2024 
